Skip to main content

DOJ Making Good on Its Publicly Declared Promise to Aggressively Pursue Healthcare Fraud

Litigation Alert

Recently announced enforcement actions from the Department of Justice (DOJ) provide further evidence that healthcare fraud remains at the forefront of its enforcement agenda. Two noteworthy examples came last week, as DOJ's National Fraud Enforcement Division announced developments in two significant Medicare fraud prosecutions involving telemedicine and durable medical equipment (DME), including new charges against a physician and a guilty plea in a $42 million DME and genetic-testing scheme.

These actions align with the National Fraud Enforcement Division's commitment to accelerate fraud investigations and focus on using data and previously developed cases to move upstream and downstream through healthcare networks, pursuing not only the entities submitting claims but also physicians, marketers, telemedicine companies, laboratories, and other participants alleged to have made the claims possible.

Two Notable Cases

On November 12, 2026, the DOJ announced an indictment against a New York physician, alleging that he participated in a $6.8 million Medicare fraud scheme involving TelevisitMD and charging conspiracy and five substantive counts of healthcare fraud. According to the indictment, TelevisitMD allowed the defendant to sign pre-filled prescriptions for orthotic braces for Medicare beneficiaries whom he allegedly had not examined or treated and, in many instances, had never spoken with. The indictment further alleges that the defendant billed Medicare for telemedicine consultations that never occurred. The case is a continuation of the prosecution of the owner of TelevisitMD, who previously pleaded guilty to conspiracy to commit healthcare and wire fraud and agreed to pay $17.9 million in restitution, and was sentenced last month to 20 years' imprisonment.

One day later, an individual defendant in Florida pleaded guilty to conspiracy to commit healthcare fraud arising from an alleged $42 million Medicare scheme involving DME and cancer genetic testing. The DOJ alleges the defendant and his co-conspirators operated three DME companies that submitted more than $26 million in false claims to Medicare, Medicare Advantage plans, and TRICARE (the healthcare program for the Department of Defense (DoD)) for braces beneficiaries did not want or need. According to the DOJ, the defendant concealed his role in the DME companies on Medicare enrollment documents and paid kickbacks to telemedicine companies to generate doctors' orders. Through another company, he allegedly sold genetic-testing orders to laboratories that paid him more than $15 million in kickbacks. The guilty plea was obtained by the Health Care Fraud Section of the DOJ's National Fraud Enforcement Division, with multi-agency investigative support from the Department of Health and Human Services Office of the Inspector General (HHS-OIG), the Federal Bureau of Investigation (FBI), the Defense Criminal Investigative Service (DCIS), and Internal Revenue Service Criminal Investigation (IRS-CI).

The Enforcement Promises Are Becoming Enforcement Actions

These cases are notable not only for the conduct at issue but for their timing. As we discussed here, in October, Assistant Attorney General (AAG) Colin M. McDonald directed the National Fraud Enforcement Division to accelerate corporate fraud enforcement and identified healthcare fraud as one of the Division's four corporate enforcement priorities. The directive also emphasized centralized oversight, rapid development of investigations, and the use of data analytics to generate investigative leads.

The two cases announced last week, as well as other recent enforcement actions, demonstrate the AAG's commitment being put into practice. They also indicate that the DOJ is scrutinizing the entire chain that produces a reimbursable claim: patient acquisition, telemedicine consultations, physician orders, DME suppliers and laboratories, and the financial arrangements connecting those participants.

The resources being brought to bear in this priority enforcement area continue to grow. The DOJ says its Health Care Fraud Strike Force Program now includes nine strike forces nationwide, supported by specialized healthcare-fraud expertise and data-driven case development.

Key Takeaways

The recent cases reinforce several practical considerations:

  • Expect scrutiny across the transaction chain. A company need not itself submit a Medicare claim to become part of a healthcare-fraud investigation.
  • Evaluate telemedicine arrangements carefully. Physician relationships, patient acquisition, medical necessity, compensation structures, and the provenance of orders can create risk for multiple participants.
  • Know what your data says. The DOJ has expressly emphasized using data analytics to identify anomalies and develop cases proactively. 
  • Do not assume investigations stop with the first prosecution. The TelevisitMD matter shows how an investigation of a company or principal often generates subsequent cases against other defendants. 
  • Understand the evolving guidance on self-disclosure. As highlighted in a previous alert, the DOJ recently clarified and streamlined the process for disclosure of potentially criminal conduct related to healthcare.

The message from the DOJ is clear: healthcare fraud is not merely an abstract enforcement goal – the National Fraud Enforcement Division is putting that priority into practice.


For more information, please contact:

Joshua Drew, jdrew@milchev.com, 202-626-5811

Kevin Lowell, klowell@milchev.com, 202-626-5837



The information contained in this communication is not intended as legal advice or as an opinion on specific facts. This information is not intended to create, and receipt of it does not constitute, a lawyer-client relationship. For more information, please contact one of the senders or your existing Miller & Chevalier lawyer contact. The invitation to contact the firm and its lawyers is not to be construed as a solicitation for legal work. Any new lawyer-client relationship will be confirmed in writing.

This, and related communications, are protected by copyright laws and treaties. You may make a single copy for personal use. You may make copies for others, but not for commercial purposes. If you give a copy to anyone else, it must be in its original, unmodified form, and must include all attributions of authorship, copyright notices, and republication notices. Except as described above, it is unlawful to copy, republish, redistribute, and/or alter this presentation without prior written consent of the copyright holder.